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ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA 
VIVEK AGARWAL & RAKESH K. CHADDA 
ABSTRACT 
Forty four schizophrenic patients were randomly assigned to receive risperidone in 4-8 mg 
doses either once daily or twice daily for 8 weeks. An open trial was conducted to determine the 
efficacy of once daily administration of risperidone as compared to twice daily administration. 
Assessment were done on Positive and Negative Syndrome Scale (PANSS) and Clinical Global 
Impression (CGI) scale Eighty two percent of the once daily patients and 79% of the twice daily 
patients showed a significant treatment response. No significant differences were observed between 
the two groups in response pattern and adverse effects at the end point. Risperidone given once 
daily was as effective as twice daily administration. 
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Risperidone, a potent serotonin (5HT2) 
and dopamine (D2) receptor blocker, has been 
shown to be an effective antipsychotic in patients 
of schizophrenia (Chouinard etal.,1993; Marder 
and Meibach, 1994; Agarwal et al , 1998). 
The largest multicentre study of 
risperidone of 1362 patients reported risperidone 
to have a bell shaped dose-response curve 
peaking at about 4 mg/day for its therapeutic 
effects (Muller-Spahn,1992). In the later studies 
also (Kleiser et al.,1995; Molier et al.,1997). 
optimal dose of risperidone in terms of both 
efficacy and safety has been found to be 4 mg/ 
day which, however, could be increased to 6-8 
mg/day if required. 
In clinical trials risperidone has been given 
twice daily mainly to minimise the risk of 
orthostatic hypotension However, in clinical 
usage orthostatic hypotension has not been the 
major problem The mean combined half-life of 
risperidone and its activity metabolite 9-hydroxy 
risperidone is about 20 hours (Owens et al., 1998) 
and it can be administered once daily Once daily 
administration is more convenient and also 
ir">roves compliance (Weiden et al ,1995). 
The present study was carried out to 
compare the therapeutic efficacy of once daily 
and twice daily administration of risperidone in 
schizophrenic patients. 
MATERIAL AND METHOD 
The study was conducted in outpatient 
setting at the Institute of Human Behaviour and 
Allied Sciences, Delhi Patients with provisional 
diagnosis of schizophrenia attending the 
outpatient services on the two particular week 
days (corresponding to the clinical unit) were 
screened for the purpose of study during the 
period of July 1998 to July 1999. ICD-10 criteria 
were used to screen the patient. Diagnosis was 
made by chart review and clinical interview. 
Patients with age less than 18 years, comorbid 
axis 1 disorder or psychoactive substance abuse, 
pregnant or lactating mothers, clinically 
significant organic or neurological disorder and 
with abnormal electrocardiogram findings were 
excluded Patients were also excluded if they 
refused to take oral medication, had been given 
depot neuroleptic 15 days prior to trial or the 
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investigational drug in 4 weeks prior to trial. Oral 
informed consent was taken from patients or 
guardian, whichever applicable. Consenting 
patients with diagnosis of schizophrenia were 
taken for study. Patients were either drug naive 
or were given one week washout if on any oral 
neuroleptic. 
At baseline detailed psychiatric and 
medical history was recorded and physical 
examination was carried out. Routine laboratory 
investigations and electrocardiogram was done. 
Psychopathology was assessed on PANSS (Kay 
et al.,1987) and CGI (NIMH,1985). Adverse 
effects were assessed on Dosage Record 
Treatment Emergent Symptom Scale (DOTES; 
Campbell and Palij, 1985). Patients were 
assessed on these scales at baseline and 
thereafter at week 1,2,4, 6, and 8. 
Patients were randomly assigned to either 
once daily or twice daily risperidone group. 
Risperidone dosages was increased from 2 mg/ 
day on day 1 to 4 mg/day on day 2 Thereafter 
patients were maintained on 4 mg/day dosage 
till 4 weeks and increased to 6 mg/day and 8 
mg/day from 5th and 7th week respectively if 
the patient did not show atleast 20% reduction 
in PANSS baseline scores. In once daily group, 
risperidone was given in the evening while in 
twice daily group it was given in morning and 
evening in equally divided doses. The total 
duration of trial was 8 weeks. 
Data was analysed using Intent-to-treat 
analysis. Data of all the patients was analysed 
who were treated for atleast 14 days. The end 
point score was defined as last observed score. 
Baseline and end point scores were compared 
using paired t-test (two tailed) for within group 
comparisons and t-test for independent samples 
for between group comparisons. 
RESULTS 
Forty four patients consented for the study 
and were taken for the trial. This included twenty 
three patients (14 male/9 female) in the once 
daily group and 21 (13 male/8 female) patients 
in the twice daily group. Two once daily patients 
discontinued the medication because of adverse 
effects while one discontinued the medication 
because of lack of response. One twice daily 
patient discontinued medication because of 
adverse effects while two were lost to follow-up. 
Thus, twenty once daily and 18 twice daily 
patients completed the trial. Mean age (range) 
was 34 (18-50) years in once daily and 37 (20-
60) years in twice daily group while duration of 
illness (mean±SE) was 5±0.9 years and 5 9±1.1 
years respectively. Both the groups were 
comparable with respect to age, sex and duration 
of illness. Mean risperidone dose was 5±0.3 mg 
in once daily group and 5.3±0 3 mg in twice daily 
group. Concomitant medication given were 
antiparkinsonian drugs in 48% once daily and 
47% twice daily patients and benzodiazepine for 
sedation in 17% once daily and 26% twice daily 
patients. According to intent to treat analysis data 
of 23 once daily and 19 twice daily patients was 
analysed as two twice daily patients lost to follow 
up in first week of trial 
Improvement was observed both on 
PANSS as well as on the CGI. Eighty two percent 
of subjects in the once daily group and 79% in 
the twice daily group (showed a 20% or greater 
reduction in total PANSS score at end point). 
Mean total PANSS scores were reduced from 
84.8 at baseline to 53.2 at end point in once daily 
group and from 78.7 to 46.2 in twice daily group. 
PANSS total and subscale scores showed a 
significant improvement (p<0.0001) from 
baseline to endpoint in each treatment group. 
The two groups did not differ in respect of 
improvement on total PANSS as well as subscale 
scores (Table) 
Severity of illness as assessed on CGI 
reduced from 5 0±0 2 to 3.3±0.2 in once daily 
group and 4.5±0.2 to 2 8±0.2 in twice daily group. 
No significant difference was found between the 
two groups. Mean CGI-improvement was 2.1 in 
both the groups at endpoint. Eighty two percent 
once daily and 79% twice daily patients had 
ratings between 1 to 3; 18% and 21% 
respectively had rating of 4. 
33 VIVEK AGARWAL & RAKESH K. CHADDA 
TABLE 
MEAN (±SE) CHANGES IN SCORES OF PANSS FROM BASELINE IN PATIENTS 
RECEIVING RISPERIDONE ONCE DAILY AND TWICE DAILY 
PANSS' 
Total 
Positive 
Negative 
General 
Psychopathology 
Once daily 
84.8H9 
23.2t1.0 
23 3±1 6 
38.311.3 
3aseline 
Twice daily 
78.7124 
21.8*1.3 
21 2H.7 
35.811.4 
Changesvs 
Once daily 
31 6±3 2 
10.411.1 
8.111.2 
13.111.5 
basel ne" 
Twice daily 
32.514.0 
10.411.5 
8.411.3 
13.811.8 
po 
ns 
ns 
ns 
ns 
a) PANSS - Positive and Negative Syndrome Scale 
b) All changes from baseline were significant (p<0 0001 
c) Significance of differences in change in once daily vs 
Atleast one adverse affect was reported by 
14 (61%) patients in the once daily group and 13 
(68%) in the twice daily group. Extrapyramidal 
syndrome, anxiety and insomnia were the 
commonest adverse effects reported by the 
patients, seen in 11,3 and 3 once daily group 
patients respectively and 9, 4 and 4 twice daily 
group patients respectively. Severe adverse 
effects included extrapyramidal syndrome in 
three patients (one in once daily and two in twice 
daily group, insomnia in one in twice daily group) 
and urinary incontinence in one patient in each 
group One once daily patient had discontinued 
the drug because of urinary incontinence and 
the other discontinued due to amenorrhea. One 
twice daily patient discontinued the drug because 
of urinary incontinence Changes in blood 
pressure and heart rate were observed in both 
the groups but were not clinically significant. 
DISCUSSION 
Risperidone in once daily regime was as 
effective as the twice daily regime in producing 
improvement in patients of schizophrenia Once 
daily regime was not also associated with any 
additional adverse effects especially the 
increased rate of orthostatic hypotension 
apprehensions about which have been 
mentioned in the earlier literature The response 
rate was similar in once daily (82%) and twice 
daily (79%) groups Further, no statistically 
significant Ji're.encc was found on f'ANSS totai 
and subscale scores at the endpoim between 
) in both the groups 
twice daily group. 
the groups. Also, CGI severity and improvement 
scores were comparable at the end point for both 
the groups. No significant difference was seen 
in respect to extrapyramidal symptoms (48% in 
once daily and 47% in twice daily group) and 
other adverse effects between the groups. 
Dropout rates were also comparable in both the 
groups (13% once daily and 14% twice daily 
patients). Only two once daily and one twice daily 
patient discontinued the drug because of adverse 
effects. These findings show that once daily 
administration of risperidone is as safe and well 
tolerated as twice daily administration. 
Risperidone is administered twice daily mainly 
because of orthostatic hypotension. However, in 
clinical practice orthostatic hypotension was not 
the major problem and in this study also none of 
the patient developed orthostatic hypotension in 
both the groups Adverse effects of the drugs 
and complex treatment regime are two important 
causes of non-compliance with treatment in the 
schizophrenic patients (Marder,1998), which 
subsequently lead to relapse of the illness. 
Therefore, simple regimes like once daily 
administration of risperidone will be convenient 
to the patients and would improve compliance 
(Weiden et al .1995). 
Limitation of the study were open trial, 
small sample size and absence of control group. 
The findingd suggest that once daily 
administration of risperidone is safe and 
effective Further controlled trials on larger 
sample with comparison of blood levels of 
risperidone are required to confirm the findings. 
34 ONCE DAILY RISPERIDONE IN SCHIZOPHRENIA 
REFERENCES 
Agarwal.A.K., Bashyam.V.S.P., 
Channabasavanna.S.M., Dhavale.H.S., Khan, 
M.A.M., Khanna,S., Pradhan.P.V., Katiyar,M., 
Rajkumar.R., Niazi.F.R., Jalali.R.K., 
Gowrishankar.R., Mishra.S.K. & Sood,O.P. 
(1998) Risperidone in Indian patients with 
schizophrenia. Indian Journal of Psychiatry, 40, 
3, 247-253. 
Campbell,M. & Palij.M. (1985) 
Measurement of side effects including tardive 
dyskinesia. Psychopharmacology Bulletin, 21,4, 
1063-1066. 
Chouinard.G., Jones,B., Remington, 
G., Bloom.D., Addington,D., MacEvan.G.W., 
Labelle.A., Beauclair.L. & Arnott.W.A. (1993) 
A Canadian multicentre placebo controlled study 
of fixed doses of risperidone and haloperidol in 
the treatment of chronic schizophrenic patients. 
Journal of Clinical Psychopharmacology, 13,25-40. 
Kay.S.R., Fiszbein.A. & Opler,L.A. 
(1987) The positive and negative syndrome 
scale (PANSS) for schizophrenia. Schizophrenia 
Bulletin, 13, 261-276. 
Kleiser.E., Lehmann.E. & Kinzler.E. 
(1995) Randomized, double blind controlled trial 
of risperidone versus clozapine in patients with 
chronic schizophrenia. Journal of Clinical 
Psychopharamcology, 15, 45-57. 
Marder,S.R.(1998) Facilitating compliance 
VIVEK AGARWAL'.MD. Senior Resident & RAKESH K CHA 
try. Institute of Human Behaviour & Allied Sciences. PO. I 
' Correspondence 
with antipsychotic medication. Journal of Clincial 
Psychiatry, 59, (suppl. 3), 21-25. 
Marder,S.R. & Meibach,R.C. (1994) 
Risperidone in the treatment of schizophrenia. 
American Journal of Psychiatry, 151, 825-835. 
Moller.H.J., Bauml.J. & Einzler.F. (1997) 
Risperidone in the treatment of schizophrenia : 
results of a study of patients from Germany, 
Austria and Switzerland. European Archives of 
Psychiatry and Clinical Neurosciences, 246, 
291-296. 
Muller-Spahn.F. (1992) Risperidone in 
the treatment of schizophrenic patients : an 
international double blind parallel group study 
versus haloperidol (abstract). Clincial 
Neuropharmacology, 15 (suppl), 90A-91A. 
National Institute of Mental Health 
(1985) Clincial Global Impression Scale. 
Psychopharmacology Bulletin, 21, 4, 839-841. 
Owens.M.J. & Risch.S.C. (1998) Atypical 
antipsychotics. In Textbook of 
Psychopharmacology, End.2, (Eds.) Schatzberg, 
A.F. & Nemeroff.C B , pp 323-348, The American 
Psychiatric Press, Inc. 
Weiden.P.J., Mott.T. & Curcio.N. (1995) 
Recognition and management of neuroleptic 
non-compliance. In : Contemporary issues in the 
treatment of schizophrenia, (Eds.) Shriqui.G.L, 
Nasrallah.H.A , pp 411-434, American 
Psychiatric Press, Inc. 
<A, MD. MAMS. Additional Professor, Department of Psychia-
: -9520, Dilshad Garden. Delhi - 110 095 
35 